Jean-Luc Herbeaux to become Hovione CEO
PR94693
LISBON, Portugal, Feb 25, 2022, /PRNewswire=KYODO JBN/--
Hovione today announced that the Board of Directors and the shareholders have
approved the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive
Officer, effective 1st April 2022.
Guy Villax, who has been Hovione’s CEO for the past 25 years will now serve as
a Member of the Board and shareholder. During his tenure, Hovione grew
tenfold. The company currently employs 2000 team members, serves the global
market from four production sites in 3 regions, and is recognized as a leader
in its field.
The Board of Directors expresses its thanks to Guy Villax for his dedication
and outstanding achievements. During his career at Hovione, Guy Villax was also
involved with the EFCG and Rx-360 associations and contributed to legislation
being passed on both sides of the Atlantic to fight fake medicines and to level
the playing field for GMP manufacturing.
“It has been a privilege and honor to lead Hovione over the last decades.
Hovione is a great company because of its people and its clients. It has been
an amazing entrepreneurial and human journey with so many projects and
unforgettable success stories. I have seen this company, founded by my parents,
growing, evolving and constantly re-inventing itself”, said Guy Villax. “Dr.
Herbeaux joined Hovione nearly two years ago as COO and from day 1 brought
change and contributed to financial and business successes. We have worked
together both on the strategy which will take Hovione to the next level and on
making this transition smooth. I am certain that both the company and our
Team-Members will continue to thrive under his leadership”, added Guy Villax.
“I am honored to be entrusted with the role of Hovione’s CEO and I am deeply
motivated to lead this team of talented professionals. Building on Guy Villax´s
legacy of innovation and customer intimacy, we will continue to work to drive
long-term growth for both ourselves and our customers maintaining the Hovione
values. Hovione puts customers and patients at the center of everything it does
and this focus will not change. Our customers can expect us to continue to
deliver on what we promise and to offer innovative approaches to their project
needs.”, said Jean-Luc Herbeaux.
Before joining Hovione in May 2020, Dr. Herbeaux held multiple high-level
leadership positions at Evonik, where he last headed the Health Care Business
Line Dr. Herbeaux holds both a Master of Science and a Ph.D. in Mechanical
Engineering with a research focus on Rheology from the University of Houston.
About Hovione
Hovione [https://www.hovione.com/] is an international company with over 60
years of experience as a Contract Development and Manufacturing Organization
(CDMO) and is currently a fully integrated supplier offering services for drug
substance, drug product intermediate and drug product. With four FDA inspected
sites [https://www.hovione.com/hovione-worldwide] in the USA, China, Ireland,
and Portugal and development laboratories in Lisbon, Portugal and New Jersey,
USA, the company provides branded pharmaceutical customers services for the
development and compliant manufacture
[https://www.hovione.com/products-and-services/contract-manufacturing-services/p
article-engineering] of innovative drugs including highly potent compounds and
customized product solutions across the entire drug life cycle. In the
inhalation area, Hovione offers a complete range of and services, from API,
formulation development and devices. Hovione was the first Chemical/
Pharmaceutical Company to became a Certified B Corp
[https://www.hovione.com/about-hovione/sustainability/b-corporation], is a
member of Rx-360, EFCG and participates actively in the industry standard
setting process. Please visit www.hovione.com
Contact
Isabel Pina | Director External Communications
ipina@hovione.com |Tel.: 0035121 982 9362
Photo - https://mma.prnewswire.com/media/1754437/Hovione.jpg
Logo - https://mma.prnewswire.com/media/1686008/Logo_Hovione_Logo.jpg
Source: Hovione
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。